The European Medicines Agency (EMA) invests in the risk of developing thromboembolism with Janssen’s pharmacy, in addition to analyzing the other three cars of covid-19, between the Russian Sputnik, for its possible use in a European Union (EU), region that is divided by the use of AstraZeneca ante the possible risk of thrombi.
The Committee of Human Pharmacists (CHMP) has undergone a real-time analysis process of the Novavax stadium vacancy since February 3; the CureVac German since February 12, and the Sputnik V from March 4, but no one has filed a calendar for the time being to apply for a conditional license from the UE, like the one issued by Pfizer & BioNtech, Moderna , AstraZeneca and Janssen.
The EMA responded on March 11 to the use of Janssen, a subsidiary of Johnson & Johnson, a vacancy that is not being used by the European Union (EU) to distribute retrievals on dose delivery by the laboratory.
The regulator confirmed that it was also investigating the incident, as it did with AstraZeneca, through a “security signal” related to cuatro cases severe coagulation coagulation posterior to the vacancy with this prepared.
The EMA analyzes data on four cases of severe blood clotting with plaques in patients who have received this vaccine beforehand, one of them during the clinical trial and three during the use of Janssen in United States, of the cual death of the person evacuated.
“We are facing a security signal, but currently in it is not clear if there is a causal association between the vacancy with Janssen’s vacancy and these affections.
It is hoped that the first injections of this vaccine from a single dose will increase in European countries ‘n partir del 19 April, according to the announcement of the pharmaceutical property, which will add 55 million units in the second quarter of this year. At the moment, it is only used in United States with a emergency authorization.
Last week, the EMA concluded an investigation into the possibility that there is a possible difference between AstraZeneca and dozens of cases of blood clots detected in the posterior seminal vesicles, by which decision included in the work of the clinic January 29.
Without embargo, and many different European countries are now limited to the national level in their use only in persons over 60 years, the EMA did not identify a risk factor such as age, sex or a specific clinical history, to explain thromboembolism reported , y recommend maintaining your uso because its benefits outweigh the secondary effects risk.
The Portuguese president, Marcelo Rebelo de Sousa, says that Portugal, which holds the presidency of the UE, is “very passionate” about the divergences he has faced in the AstraZeneca holiday and his suffering impossibility of launching a common position on the 27th about the evacuation campaign.
While Novavax and Curevac do not currently have sobresaltos, Sputnik V’s vacancy is controversial. The EMA will set up a “Clinical Practice Inspection” in Russia on the form in which voluntary tests are carried out to determine whether appropriate procedures are being carried out at a scientific and ethical level.
Moscow has indicated that militaries and employees of the State participated in the evacuation, unrolled in a state-funded and funded laboratory of the Russo de Inversión Directa (RDIF, by its seal in England), a sober fund of the Kremlin, which signaled which has no pressure on the persons involved in the attempts.
In addition, the EUobserver digital diary contains four murals in Russia (for problems related to the coronary arteries, pulses or sugar in the blood) and other ses desarrollaron medical complications in the posterior days to receive Sputnik V, although it is not clear that these cases have a direct relationship with the evacuation.
Although it has not yet received the response from European scientists, it has signed a centralized contract with Brussels, Berlin and the Russian Direct Investment Fund (FIDR) and has opened bilateral negotiations on future acquisitions by Germany. of Sputnik V, when it came to the good performance of the EMA.
ROA